CMS published revised guidance on December 14, 2023 to defer its decision to require 340B point-of-sale modifiers for Part D drugs beginning in 2026. RWC-340B submitted comments to CMS’s initial proposal…
On January 27, 2020, the U.S. Government Accountability Office (GAO) released a report (the Report) assessing oversight by the Department of Health and Human Services (HHS) of the 340B duplicate…
On January 8, 2020, the Centers for Medicare & Medicaid Services (CMS) issued an Informational Bulletin (Bulletin) outlining CMS’s view of current “best practices” by states to avoid 340B duplicate…
On Thursday, July 25, 2019, the Senate Finance Committee voted to approve a wide-ranging drug pricing bill, the Prescription Drug Pricing Reduction Act (PDPRA) of 2019. The bill seeks to…
Earlier today, HHS issued a Final Rule that will require pharmaceutical manufacturers to disclose the wholesale acquisition cost (“WAC”) in direct-to-consumer TV advertisements for all Medicare and Medicaid covered drugs. …
On January 7, California Gov. Gavin Newsom signed an executive order instructing Medi-Cal to transition all pharmacy services for Medi-Cal managed care to fee-for-service (FFS) by January 2021. The directive…
CMS finalized yesterday a nearly 30 percent cut in Medicare Part B reimbursement to hospitals for 340B physician-administered drugs. The payment cut will go into effect January 1, 2018. Currently,…
The Centers for Medicare and Medicaid Services (CMS) issued its long awaited regulations on Medicaid reimbursement and rebates for so-called “covered outpatient drugs” today. The rule is relevant to RWCs because drug manufacturers…